Glucotrack (Nasdaq:GCTK) announced that it plans to effect a 1-for-60 reverse stock split of its issued and outstanding common stock. Rutherford, New Jersey-based Glucotrack — maker of a long-term implantable continuous blood glucose monitor (CBGM) — intends for the split to go into effect when the market opens on Monday, June 16, 2025. Under the terms […]
Wall Street Beat
Embecta eyes shift from insulin delivery to broader medical supplies focus
Embecta (Nasdaq:EMBC) today revealed its phased plan to create value and shift priorities toward broader medical applications. The pure-play diabetes technology company has endured ups and downs since its 2022 spin-off from BD. That includes an FDA approval for a disposable insulin patch pump system in September 2024, only to be followed by the discontinuation […]
Medtronic to separate Diabetes business unit
Medtronic (NYSE:MDT) announced today that it intends to separate its Diabetes business into a new standalone company. The medtech giant said the strategic decision can create “a more focused Medtronic” with a more simplified portfolio in high-margin growth markets. At the same time, it creates an independent, scaled leader in diabetes. The new company — […]
Beta Bionics posts Q1 sales beat, raises 2025 guidance
Beta Bionics (Nasdaq:BBNX) shares remained unmoved after hours today on first-quarter results that topped the consensus sales forecast. Following its first-quarter performance, Beta Bionics increased its full-year guidance. After previously projecting between $80 million and $85 million in revenue, it now expects between $82 million and $87 million. The Irvine, California-based automated insulin delivery technology developer […]
Analysts are high on Dexcom after Q1 results, $750M repurchase program
Dexcom (Nadsaq:DXCM) shares rose after hours today on first-quarter results that came in mixed compared to the consensus forecast. Shares of DXCM ticked up 3% to $72.30 apiece in post-market trading on Thursday. However, before hours on Friday, shares fell 1.6% to $70.26 apiece. The San Diego-based continuous glucose monitor (CGM) maker reported profits of […]
Tandem stock rises after hours on Q1 sales beat
Tandem Diabetes Care (Nasdaq:TNDM) shares got a boost after the market closed today on first-quarter results that beat the consensus forecast. Shares of TNDM ticked up 6.2% to $17.89 apiece in post-market trading today. The San Diego-based automated insulin delivery technology company reported losses of $130.56 million. That equals 1.97 per share on sales of […]
Ypsomed to sell diabetes business, insulin delivery tech to TecMed for $517.7M
Ypsomed announced today that it agreed to sell its diabetes care business to TecMed for up to approximately $517.7 million (CHF 420 million). Burgdorf, Switzerland–based Ypsomed says the sale helps it focus on strengthening its position in the subcutaneous self-injection market. TecMed — also based in Burgdorf — can now add Ypsomed’s insulin delivery technology […]
Retractable Technologies cuts workforce as it reduces reliance on China amid trade war
Retractable Technologies (NYSE:RVP) announced today that it reduced its workforce by approximately 7%. The Little Elm, Texas-based maker of products like syringes and needles said the move comes as it allocates more resources to the U.S. It aims to increase U.S. manufacturing capabilities and reduce reliance on products produced in China. According to a news […]
How ICU Medical plans to mitigate tariff impact
Needham analysts report that ICU Medical (Nasdaq: ICUI) has a plan in place to handle its exposure to the tariffs imposed by the Trump Administration. Medtech stocks already took a hit last month as in response to Trump’s tariff policies. Trump’s rollout of new taxes on imports from nearly all countries last week triggered the latest market dip. […]
Beta Bionics posts Q4 sales beat to cap off ‘momentum-building year’
Beta Bionics (Nasdaq:BBNX) shares rose after hours today on fourth-quarter results that topped the consensus sales forecast. Shares of BBNX ticked up nearly 2% to $15.50 apiece in poost-market trading today. This is the company’s first quarterly earnings report after it went public through a $234.6 million IPO in January. The Irvine, California-based automated insulin […]
